{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:16:49Z","timestamp":1788225409663,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010908","name":"Virginia Catalyst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010908","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027210","name":"Virginia Catalyst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.isci.2026.116519","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:59:14Z","timestamp":1782763154000},"page":"116519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual BAFF and APRIL inhibition with TACI-Fc depletes IgA plasma cells and ameliorates lupus nephritis"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0301-2811","authenticated-orcid":false,"given":"Andrea","family":"Daamen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahua","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"St. Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrie","family":"Grammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lipsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116519_bib1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.116519_bib2","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1084\/jem.20100086","article-title":"Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice","volume":"207","author":"Scapini","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.116519_bib3","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.116519_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.116519_bib5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116519_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12810","article-title":"BAFF inhibition in SLE-Is tolerance restored?","volume":"292","author":"Jackson","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.isci.2026.116519_bib7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1006\/clim.2001.5079","article-title":"NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci","volume":"100","author":"Waters","year":"2001","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.isci.2026.116519_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1147526","article-title":"Molecular mechanisms governing the progression of nephritis in lupus prone mice and human lupus patients","volume":"14","author":"Daamen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116519_bib9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/16.7.1479","article-title":"Severe non-proliferative lupus nephritis with predominant sub-endothelial IgA deposits","volume":"16","author":"Florquin","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.isci.2026.116519_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163085","article-title":"The Level of IgA Antibodies to Endothelial Cells Correlates with Histological Evidence of Disease Activity in Patients with Lupus Nephritis","volume":"11","author":"Kondo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.116519_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/cei.13180","article-title":"Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual","volume":"194","author":"Frodlund","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.isci.2026.116519_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/09612033221074184","article-title":"IgA anti-dsDNA antibodies: A neglected serological parameter in systemic lupus erythematosus","volume":"31","author":"Lee","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.isci.2026.116519_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl3848","article-title":"Lupus IgA1 autoantibodies synergize with IgG to enhance plasmacytoid dendritic cell responses to RNA-containing immune complexes","volume":"16","author":"Waterman","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.116519_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2026.116519_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","article-title":"Kidney fibrosis: from mechanisms to therapeutic medicines","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.isci.2026.116519_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1046\/j.1440-1827.2001.01283.x","article-title":"Glomerular expression of alpha-smooth muscle actin reflects disease activity of IgA nephropathy","volume":"51","author":"Kaneko","year":"2001","journal-title":"Pathol. Int."},{"key":"10.1016\/j.isci.2026.116519_bib17","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.4049\/jimmunol.177.4.2671","article-title":"Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF","volume":"177","author":"Jacob","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.116519_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2567.2006.02500.x","article-title":"Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice","volume":"120","author":"Ju","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.isci.2026.116519_bib19","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/art.39210","article-title":"Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors","volume":"67","author":"Jacob","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.isci.2026.116519_bib20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1172\/JCI26385","article-title":"Similarities and differences between selective and nonselective BAFF blockade in murine SLE","volume":"116","author":"Ramanujam","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.116519_bib21","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/art.27368","article-title":"Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice","volume":"62","author":"Ramanujam","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.isci.2026.116519_bib22","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.isci.2026.116519_bib23","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.yexcr.2011.02.005","article-title":"BAFF inhibition: a new class of drugs for the treatment of autoimmunity","volume":"317","author":"Liu","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.isci.2026.116519_bib24","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1097\/TP.0000000000002992","article-title":"Anti-BAFF Treatment Interferes With Humoral Responses in a Model of Renal Transplantation in Rats","volume":"104","author":"Steines","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.isci.2026.116519_bib25","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.4049\/jimmunol.180.11.7394","article-title":"B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation","volume":"180","author":"Chang","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.116519_bib26","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1126\/science.1061964","article-title":"An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway","volume":"293","author":"Schiemann","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.116519_bib27","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.isci.2026.116519_bib28","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/art.33458","article-title":"Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice","volume":"64","author":"Jacob","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.isci.2026.116519_bib29","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.20290","article-title":"Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI","volume":"50","author":"Liu","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.isci.2026.116519_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","article-title":"TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS","volume":"15","author":"Gross","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.116519_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcp.21561","article-title":"APRIL hath put a spring of youth in everything: Relevance of APRIL for survival","volume":"218","author":"Kimberley","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.isci.2026.116519_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.isci.2026.116519_bib33","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.isci.2026.116519_bib34","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116519_bib35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.isci.2026.116519_bib36","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.isci.2026.116519_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today"},{"key":"10.1016\/j.isci.2026.116519_bib38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116519_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0022-1759(90)90380-E","article-title":"Subnucleosome structures as substrates in enzyme-linked immunosorbent assays","volume":"134","author":"Burlingame","year":"1990","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.isci.2026.116519_bib40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.isci.2026.116519_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/B978-0-12-801430-1.00005-6","article-title":"Tools and techniques to study ligand-receptor interactions and receptor activation by TNF superfamily members","volume":"545","author":"Schneider","year":"2014","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.isci.2026.116519_bib46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0076-6879(00)22031-4","article-title":"Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins","volume":"322","author":"Schneider","year":"2000","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.isci.2026.116519_bib41","doi-asserted-by":"crossref","first-page":"33127","DOI":"10.1074\/jbc.M305754200","article-title":"Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF","volume":"278","author":"Pelletier","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2026.116519_bib42","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/eji.201746934","article-title":"A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells","volume":"47","author":"Haselmayer","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2026.116519_bib43","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.4049\/jimmunol.158.11.5566","article-title":"Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice","volume":"158","author":"Vyse","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.116519_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226018948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226018948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:05:50Z","timestamp":1788224750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226018948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589004226018948"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116519","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual BAFF and APRIL inhibition with TACI-Fc depletes IgA plasma cells and ameliorates lupus nephritis","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116519"}}